2025-08-29 04:12:58
Latest Post
Himadri Speciality Chemical Ltd Secures ISCC PLUS Certification
HCLSoftware delivers Digital Independence with AI-Powered Sovereign Collaboration Solutions for Business-Critical Infrastructure
Dr. Agarwal's Health Care Limited and Dr. Agarwal's Eye Hospital Limited announce Merger
SAMHI signs agreement to Lease for ~260-room Mid-Scale Hotel in Hyderabad's Financial District
Rail Vikas Nigam Ltd signs JV agreement with Texmaco Rail & Engineering Ltd
Stock Report
Medicamen Biotech Ltd Q4 FY2021-22 consolidated PAT declines to Rs. 2.74 crore
Posted On : 2022-05-25 19:39:18( TIMEZONE : IST )
MEDICAMEN BIOTECH LTD. has reported Consolidated financial results for the period ended March 31, 2022.
Financial Results (Q4 FY2022) - QoQ Comparison
The company has reported total income of Rs. 23.0914 crores during the period ended March 31, 2022 as compared to Rs. 33.4684 crores during the period ended December 31, 2021.
The company has posted net profit / (loss) of Rs. 2.7454 crores for the period ended March 31, 2022 as against net profit / (loss) of Rs. 3.7785 crores for the period ended December 31, 2021.
The company has reported EPS of Rs. 2.25 for the period ended March 31, 2022 as compared to Rs. 3.09 for the period ended December 31, 2021.
| Financials | Q4 FY2022 | Q3 FY2022 | % Change |
| Total Income | ₹ 23.0914 crs | ₹33.4684 crs |  -31.01% |
| Net Profit | ₹2.7454 crs | ₹3.7785 crs | -27.34% |
| EPS | ₹2.25 | ₹3.09 | -27.18% |
Financial Results (Q4 FY2022) - YoY Comparison
The company has reported total income of Rs. 23.0914 crores during the period ended March 31, 2022 as compared to Rs.21.7760 crores during the period ended March 31, 2021.
The company has posted net profit / (loss) of Rs.2.7454 crores for the period ended March 31, 2022 as against net profit / (loss) of Rs.3.6469 crores for the period ended March 31, 2021.
The company has reported EPS of Rs.2.25 for the period ended March 31, 2022 as compared to Rs.2.99 for the period ended March 31, 2021.
| Financials | Q4 FY2022 | Q4 FY2021 | % Change |
| Total Income | ₹ 23.0914 crs | ₹21.7760 crs |  6.04% |
| Net Profit | ₹2.7454 crs | ₹3.6469 crs | -24.72% |
| EPS | ₹2.25 | ₹2.99 | -24.75% |
Financial Results (Year Ended FY2022) - YoY Comparison
The company has reported total income of Rs.117.1653 crores during the Financial Year ended March 31, 2022 as compared to Rs.113.4701 crores during the Financial Year ended March 31, 2021.
The company has posted net profit / (loss) of Rs.14.8971 crores for the Financial Year ended March 31, 2022 as against net profit / (loss) of Rs.12.1294 crores for the Financial Year ended March 31, 2021.
The company has reported EPS of Rs.12.19 for the Financial Year ended March 31, 2022 as compared to Rs.9.93 for the Financial Year ended March 31, 2021.
| Financials | Year Ended FY2022 | Year Ended FY2021 | % Change |
| Total Income | ₹117.1653 crs | ₹113.4701 crs | 3.26% |
| Net Profit | ₹14.8971 crs | ₹12.1294 crs | 22.82% |
| EPS | ₹12.19 | ₹9.93 | 22.76% |
Shares of MEDICAMEN BIOTECH LTD. was last trading in BSE at Rs. 601.75 as compared to the previous close of Rs. 636.50. The total number of shares traded during the day was 1013 in over 120 trades.
The stock hit an intraday high of Rs. 650.30 and intraday low of 599.00. The net turnover during the day was Rs. 625500.00.
